Whitehawk Therapeutics (WHWK) Research & Development (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Research & Development data on file, last reported at $17.2 million in Q1 2026.

• Research & Development for Q1 2026 came in at $17.2 million, up 96.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $99.4 million (up 115.05% YoY), and the FY2025 annual result was $91.0 million, up 78.25% from the prior year.
• Research & Development declined to $17.2 million in Q1 2026 per WHWK's latest filing, from $19.0 million in the prior quarter.
• Over five years, Research & Development peaked at $48.8 million in Q2 2025 and troughed at $6.8 million in Q1 2022.
• A 5-year average of $14.2 million and a median of $12.8 million in 2023 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 272.79% in 2025 and fell as far as 35.35% in 2025.
• A 5-year view of Research & Development shows it stood at $9.4 million in 2022, then surged by 36.26% to $12.8 million in 2023, then increased by 12.37% to $14.3 million in 2024, then soared by 32.58% to $19.0 million in 2025, then fell by 9.41% to $17.2 million in 2026.
• Business Quant data shows WHWK's Research & Development at $17.2 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.